I really don't like any comparisons between NWBO and CVM, but I must admit there are reasons the comparisons could be meaningful. The difference is that CVM has been tried in many indications and failed, whereas to date our vaccines seem to succeed where they've been tried. While DCVax-L was originally developed for GBM, so that's where extensive testing has been done, it's benefits appear to be far more universal.
DCVax-Direct evolved from DCVax-L and potentially makes the tumor itself into a vaccine producer that fight the cancer. As I understand it, if a person had multiple inoperable tumors caused by the same cancer, an injection of DCVax-Direct into one, or a few of them would still result in the body fighting them all. If I'm wrong about this, please let me know.
I'm very much hoping that DCVax-Direct will be in trial again shortly, I've already approached the company about a use for it.
Gary
News 
Market Data 
Discover 
AI
